REVIEW ARTICLE

Regulatory T cells in inflammation and resolution of acute lung injury

Linlin Wang | Weipeng Jiang | Xiaocen Wang | Lin Tong
Yuanlin Song

1Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
2Shanghai Key Laboratory of Lung Inflammation and Injury, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
3Shanghai Institute of Infectious Disease and Biosecurity, Shanghai, China
4Shanghai Respiratory Research Institute, Shanghai, China
5National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
6Jinshan Hospital of Fudan University, Shanghai, China

Correspondence
Yuanlin Song and Lin Tong, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.
Email: song.yuanlin@zs-hospital.sh.cn and tong.lin@zs-hospital.sh.cn

Funding information
Shanghai Municipal Key Clinical Specialty, Grant/Award Number: shsclzdk0220; Clinical Research Plan of SHDC, Grant/Award Number: SHDC2020CR5010-002; Shanghai Municipal Science and Technology Major Project; Science and Technology Commission of Shanghai Municipality, Grant/Award Numbers: 20Z11901000, 20DZ2261200, 20XD1401200; National Key R&D Plan, Grant/Award Number: 2020YFC2003700; National Natural Science Foundation of China, Grant/Award Numbers: 8200087, 82130001

Abstract

Introduction: Acute respiratory distress syndrome (ARDS) is characterized by hypoxemia and increased lung permeability and would result in acute respiratory failure and with high mortality. In patients who survive from acute lung injury (ALI)/ARDS, it is an active process of the transition from injury to resolution depending on the coordinated immune system. The roles of regulatory CD4+ T cells (Tregs) are now gradually being clarified during inflammation and resolution of ARDS. However, clear conclusions about roles of Tregs in ALI/ARDS are only a few.

Objective: This review provides an overview of phenotype, differentiation, and suppressive mechanisms of Tregs and focuses on keys of biology of Tregs in alveolar space during the inflammatory response and resolution of ALI/ARDS.

Data Source: Literature search of Web of Science, PubMed, and EMBASE was made to find relative articles about Tregs in ALI/ARDS. We used the following search terms: Tregs, ALI, ARDS, inflammation, and resolution.

Conclusion: More and more studies have indicated Tregs involved in the processes of inflammation and resolution of ALI/ARDS. A deep understanding of the roles of Tregs may indicate new treatments for patients of ARDS. Therapies aimed at expansion or adaptive transfer of Tregs could be an effective therapy to ARDS patients.

Linlin Wang, Weipeng Jiang, and Xiaocen Wang contributed equally.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. The Clinical Respiratory Journal published by John Wiley & Sons Ltd.
1 | INTRODUCTION

The acute onset of ALI and ARDS is mainly manifested by respiratory distress and refractory hypoxemia with high mortality and poor prognosis. Now, the main clinical treatment methods are supportive treatment. Except for small tidal volume mechanical ventilation and prone position ventilation, which can reduce the mortality rate of ALI/ARDS, there are no other effective drug treatment measures. The existing schemes cannot achieve satisfactory results, and the mortality is still up to 40%. In addition to the above treatments, research on regulating the immune response of ALI/ARDS is also receiving increasing attention. Studies indicated that the recovery of lung injury depends on highly coordinated immune system.

In one our retrospective study, we found NLR (neutrophil and lymphocyte ratio) was significantly correlated with the prognosis of the ARDS. The prognosis was poor when the ratio was greater than 14, indicating that lymphocytes may play an important role in the onset and development of ARDS.

At present, the most widely studied lymphocyte subsets in ALI/ARDS are regulatory T cells (Tregs). In alveolar space, the processes of inflammation and resolution are closely related to the subpopulations and functions of Tregs. Researchers have identified the phenotype, mechanisms, and signal pathways of Tregs involved in acute inflammation and resolution in ALI/ARDS. Now, we will focus on keys of Tregs biology (subpopulations, differentiation, and function) of alveolar space during the inflammatory response and resolution of ALI/ARDS and explore new areas of therapeutic potential of ARDS.

2 | PHENOTYPE AND DEVELOPMENT OF Tregs

Tregs play an important role during the suppression of immune response through different mechanisms. Tregs mainly include two subgroups: nTregs (thymus-derived Tregs) and iTregs (induced Tregs), which peripherally antigen-induced Tregs generated in the periphery from naïve CD4^+ T cells under certain antigenic stimuli or suppressor cytokines. iTregs are usually more plastic than nTregs. Although two Treg subpopulations exhibit different developmental mechanisms, they have a synergistic effect to maintain immune homeostasis and share similar phenotypes and suppressive function.

The precursors that express TCRs with high affinity for self-antigens can develop into nTregs. nTreg differentiation in thymus consists of two steps. The combination of a strong TCR signal with costimulatory molecules result in the upregulation of CD25 of naïve CD4^+ T cells. Then, signal transducer and activator of transcription 5 (STAT-5) are the downstream of CD25, can bind a regulatory sequence in the Foxp3 gene, and then promote Foxp3 expression, which is a necessary marker during the development and function of Tregs in the thymus and peripheral lymphoid organs, and Foxp3 locus conserved noncoding regions (CNS) of the regions also involved in Treg induction and stability (Figure 1A). After generation in thymus, nTregs migrate to the periphery to perform their suppressive function.

nTregs express constitutively CD4 and CD25, but CD25 is also upregulated in effector T cells (Teffs) when activated. nTregs also constitutively express CTLA-4 (cytotoxic T Lymphocyte antigen 4), CD62L, CD103, and GITR (glucocorticoid-induced tumor necrosis factor receptor related protein), but expression of these markers is also affected by T cell activation and do not provide more specificity than CD25. nCD127 have been thought to be characteristic of nTregs, but its expression is downregulated after Teff activation. Thus, CD127 is only useful to identify Tregs in non-inflammatory conditions. nTregs also express some non-specific markers such as LAG-3 (protein lymphocyte activation gene 3) and TLRs 4, 5, 7, and 8.

iTregs express different levels of CD25. Most of iTregs highly express CD25, and a small group expresses small amounts of CD25, but both populations express Foxp3 (Figure 1B). iTregs are generated in the periphery induced from naïve CD4^+ T cells with anti-inflammatory cytokines and dendritic cells (DCs). A high concentration of TGF-β is a critical cytokine for the generation and phenotype in T cells. TGF-β affected the peripheral pool of Tregs and the role of TGF-β in development of iTregs was initially refuted. However, recent studies have showed that TGF-β is necessary requirement for the generation of iTregs, indicating that TGF-β also can induce Foxp3 expression of thymic Treg precursors in the context of TCR. Tolerogenic CD103^+DCs can generated RA (retinoic acid) and 1,25(OH)2D3 (1,25-dihydroxyvitamin D3) to provide a favorable environment for iTregs differentiation. 1,25(OH)2D3 combined with IL-2 can induce both CTLA-4 and Foxp3 expression of iTregs. The PD-1/PD-L1 signaling also plays critical
roles in the generation, homeostasis, and plasticity of Foxp3+ iTregs. The most common subgroups of Tregs include Tr1 cells (Type 1 regulatory T) and Th3 cells. Tr1 cells express low and transient levels of Foxp3 and secretion of high amounts of IL-10, which induce anergy and low cell proliferation. They also produce IFN-γ, TGF-β, and IL-15 and low levels of IL-2 and IL-4 and induce anergy and low cell proliferation by secretion of IL-10. There is no specific marker for Th1 cells, although some research has shown that GATA is a potential candidate. Th3 cells originate from CD4+ T cells stimulated by TGF-β and play critical role in oral tolerance by secretion of TGF-β and IL-10.

Both nTregs and iTregs express CD25 and Foxp3. Thus, it remains challenging to distinguish these two subsets. Helios, Nrp-1 (neuropilin-1), and FR4 (folate receptor 4) are candidates for this discrimination. But these are no specific markers to distinguish nTregs from iTregs. Although nTregs can distinguish from iTregs by higher expression of Helios, a small group of human nTregs does not express Helios. Furthermore, recent studies have reported that iTregs could also express Helios. Although nTregs exclusively express Nrp-1, Nrp-1 can also be induced in activated Teffs in humans. High amounts of FR4 are found to express constitutively on nTregs, but it also expressed by iTregs. Thus, the contribution of nTregs and iTregs to the disease would be limited by the lack of definite markers, particularly in humans.

3 | SUPPRESSIVE MECHANISMS OF Tregs

TCR repertoires of nTregs and iTregs are different leads to their function are distinct. iTregs are mainly involved in the tolerance to non-self-antigens while nTregs are preferentially responsible for control of auto-specific responses. Tregs can regulate both innate and adaptive immune cells in various pathophysiological microenvironment though different suppressive mechanism.

Two main types of suppressive mechanisms of Tregs are contact-dependent and contact-independent. Tregs can regulate maturation and function of APC (antigen presenting cell) through the interaction of CTLA-4, Nrp-1, and LAG-3 expressed on Tregs with the CD80/86 costimulatory molecules, MHC class II, and Sema4a expressed on APC. Tregs can also induce direct killing of Teffs through interaction of Gal-9 expressed by Tregs and Tim-3 expressed by Teffs. Tregs can express CD39/CD73 ectoenzymes to cleavage of ATP into adenosine. Interaction of adenosine with the A2A receptor increases cAMP levels of target cells, thus inhibit cell proliferation of these target cells. Adenosine combined with A2A receptor expressed on Tregs can improve expression of Foxp3 and Tregs function.

Tregs can also secret anti-inflammatory cytokines, such as TGF-β, IL-10, and IL-35. These immunosuppressive cytokines in turn induce the development of iTregs. TGF-β can inhibit the proliferation and differentiation of Th1 and Th2 by downregulating of the transcription of T-bet and GATA-3. High level of TGF-β also affects Th17 cells function. IL-10 can suppress T cells responses by downregulating of IFN-γ, IL-2, and GM-CSF. Furthermore, IL-10 can induce IgG4 and suppress IgE of B cells to induce immune tolerance. IL-35 is a novel anti-inflammatory cytokine specifically secreted by Tregs, and necessary for maximal suppressive function of Tregs, can induce the development of iTregs, suppress the proliferation of Th1 and Th17 cells by inhibiting the G1 phase of cell division of early T cell rest, and inhibit development and proliferation of Th2 by repressing...
GATA3 transcription and IL-4 secretion. IL-35 can also regulate the plasticity of Th2, mediate differentiation of Th2 cells to Tregs (Figure 2).

IL-2 is required to expand Tregs and to induce their suppressive function in vitro. However, in vivo, Tregs are strong competitors for IL-2 compared with their target cells via constitutively expressing CD25. Lack of IL-2 causes apoptosis of target cells through the Bcl-2/Bim and independently of PRF/Fas signaling pathway (Figure 2). Mice deficient in IL-2 develop an unstable population of Tregs and subsequently acquire lymphoproliferative disease. From this side, it is difficult to reconcile with the idea that IL-2 absorption plays a relevant role as an effector mechanism in vivo. Recent studies have proposed that Tregs can induce direct killing of Teffs through the GZB (granzyme B) production or by the interaction of Gal-9 (galectin 9) expressed by Tregs with Tim-3 (T-cell immunoglobulin and mucin domain-containing protein 3) expressed by Teff. GZB also can lyse myeloid APC through the interaction of CD2 and LFA-1 (lymphocyte function-associated antigen-1) expressed by Tregs with CD58 and CD54 expressed by myeloid APC (Figure 2).

FIGURE 2 Tregs regulate immune responses through multiple suppressive mechanisms. Tregs can inhibit Teffs through the suppressive cytokines IL-10, IL-35, and TGF-β. Tregs can disrupt metabolic functions of Teff through co-expressing CD39/CD73 generating adenosine or IL-2 deprivation. Interaction of CTLA-4, LAG-3, and Nrp1 expressed by Tregs with CD80/86 costimulatory molecules and Sema4a and MHCII expressed by APC can suppress maturation and function of Tregs, lead to production of IDO, and finally prevent maturation of APC maturation and activation of Teffs. Tregs also can induce direct killing of Teffs through the production of GZB or the interaction between Gal-9 expressed by Tregs with Tim-3 expressed by Teffs. GZB also can lyse myeloid APC through the interaction of CD2 and LFA-1 expressed by Tregs and CD58 and CD54 expressed by myeloid APC.
in ALI/ARDS, then effective therapies could be designed to treat ALI/ARDS by regulating the number and function of Tregs either endogenously or exogenously.

In Tregs, CD4⁺CD25⁺Foxp3⁺Tregs are the most studied in ALI/ARDS. D’Alessio et al. first show that CD4⁺CD25⁺Foxp3⁺Tregs could mediated the active resolution of ALI mouse model.⁸ Many studies have indicated that CD4⁺CD25⁺Foxp3⁺Tregs are associated with severity of ALI/ARDS. Adamzik group found CD4⁺CD25⁺Foxp3⁺Tregs could be activated in ARDS patients and increased in alveola and even could predict poor outcome of ARDS.⁶⁸ Sebastien et al. also found that the quantity and function of Tregs changed in ARDS patients.⁶⁹ A prospective, observational study performed by Yu group indicated ratio of Th17/Treg ratio >0.79 was the independent predictor for 28-day mortality in ARDS patients.⁷⁰ Our recent studies also found there was imbalance of Tregs and Th17 cells and Tregs/Th17 ratio down-regulated in LPS-induced ALI model.⁷¹

The main mechanisms of CD4⁺CD25⁺Foxp3⁺Tregs in alveolar to improve ALI resolution are mediated by inducing neutrophil apoptosis and suppression of macrophage anti-inflammatory cytokine secretion,⁸,⁷² control fibrocyte recruitment to lung to inhibit the fibroproliferation though CXCL12-CXCR4 axis,⁷³ CD73-dependent adenosine generation.⁷⁴ Singer group also found that the number and Foxp3 expression, activation state, suppressive phenotype, and proliferative capacity of CD4⁺CD25⁺Foxp3⁺Tregs in lung enhanced in mice treated by DNA methyltransferase inhibitor indicated that epigenetic pathways are very likely to be novel targets for the treatment of ARDS.⁷⁵ Epithelial repair also plays important role in resolution of ALI. Data of Dial et al. indicated that Foxp3⁺Tregs can secret keratinocyte growth factor (KGF) to enhance alveolar epithelial proliferation.⁷⁶ Moreover, Tregs also can directly exert tissue repair function, at least in part, through production of amphiregulin in influenza-induced ALI model (Figure 3).⁷⁷

The potential mechanism of Treg suppress the inflammation and promote of resolution of ALI. Neutrophils, macrophages, and Th17 cells are recruited into alveola, and release inflammatory mediators lead to damage of endothelium, thus pulmonary edema during ALI. IL-10 and TGF-β secretion of Tregs can inhibit the proliferation and function of Th17 cells and macrophages. TGF-β also can mediate apoptosis of neutrophil apoptosis and cytokines secretion of macrophage, promote the barrier repair. Tregs also can control of fibrocyte recruitment to the lung to inhibit the fibroproliferation. Tregs also can promote resolution of ALI through CD73-dependent adenosine generation. Treg number and function can be partly enhanced by DNA methyltransferase inhibition to accelerate repair of lung injury. Moreover, Tregs exert tissue repair function by expression KGF and amphiregulin.
Clarifying the roles of Tregs in ALI resolution may lead to the design of new treatments for patients with ARDS. And therapies aimed at expansion or adaptive transfer of Tregs to ARDS patients could be an effective approach.

Studies have found leukotriene B4 Receptor (BLT1) and alanyl-glutamine (Ala-Gln) could recruit CD4+CD25+Foxp3+ Tregs of alveoli. The blockade of LTB4-BLT1 pathway significantly decreased Tregs numbers in BALF and impaired ALI resolution.78 And intragastric gavage Ala-Gln could regulate the polarization of Tregs and Th17 cells to promote the resolution of lung inflammation.79 Moreover, our previous studies also indicated that lung-resident mesenchymal stem cell can maintain balance of Tregs and Th17 cells and upregulate Treg/Th17 ratio.80 These data above tell us that finding ways to increase the number or function of Tregs or upregulate the Treg/Th17 cell ratio may be an effective way to alleviate lung injury and promote lung repair.

The adoptive transfer of regulatory lymphocytes to patients with ALI is a good idea. D’Alessio et al. found the transfer of Tregs significantly improved survival rate and resolution of ALI.8 But there are concerns that Tregs tend to exhibit remarkable plasticity. It remains unknown whether Tregs differentiate into effector T cells after adaptive transfer to ARDS patients. Moreover, therapeutic effect of Tregs depend on its relative contributions and the timing during the course of ALI initiation, pathogenesis and resolution. Up to now, there is only evidence of Tregs transfer to promote the resolution of ALI, but no studied pay attention to the timing of Tregs.

ARS is a hard clinical problem with high mortality in critically ill patients. No specific therapies are available. Studies of ALI indicate that Tregs attempt to promote the resolution of ALI by regulating actively innate and adaptive immune responses. Identifying how to best isolate and augment Tregs in vivo or ex vivo and avoid Tregs depletion are critical aims that are the potential treatment of ALI/ARDS.

ACKNOWLEDGMENTS
This study was supported by National Natural Science Foundation of China (8200087 and 82130001), National Key R&D Plan (2020YFC2003700), Science and Technology Commission of Shanghai Municipality (20211901000, 20DZ2261200, and 20XD1401200), Shanghai Municipal Science and Technology Major Project, Clinical Research Plan of SHDC (SHDC2020CR5010-002), and Shanghai Municipal Key Clinical Specialty (shslczdzk02201).

CONFLICT OF INTEREST
The authors declare that they have no competing interests.

ETHICS STATEMENT
The Ethics statement is not applicable in this review.

AUTHOR CONTRIBUTIONS
Linlin Wang, Weipeng Jiang, and Xiaocen Wang involved in writing manuscript draft, searched for literatures, and contributed to final draft. Yuanlin Song and Lin Tong revised the manuscript. All authors have read and approved the final draft of the manuscript for publication.

DATA AVAILABILITY STATEMENT
Research data are not shared.

ORCID
Linlin Wang https://orcid.org/0000-0001-9332-284X
Weipeng Jiang https://orcid.org/0000-0002-3028-891X
Xiaocen Wang https://orcid.org/0000-0002-6815-1054

REFERENCES
1. Guérin C, Beuret P, Constantin JM, et al. A prospective international observational prevalence study on prone positioning of ARDS patients: the APRONET (ARDS Prone Position Network) study. *Intensive Care Med*. 2018;44(1):22-37. doi:10.1007/s00134-017-4996-5
2. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. *J Clin Invest*. 2012;122(8):2731-2740. doi:10.1172/JCI60331
3. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. *Nat Immunol*. 2005;6(12):1191-1197. doi:10.1038/ni1276
4. Savill J. Apoptosis in resolution of inflammation. *J Leukoc Biol*. 1997;61(4):375-380. doi:10.1002/jlb.61.4.375
5. Henson PM. Dampening inflammation. *Nat Immunol*. 2005;6(12):1179-1181. doi:10.1038/nl1205-1179
6. Henson PM, Hume DA. Apoptotic cell removal in development and tissue homeostasis. *Trends Immunol*. 2006;27(5):244-250. doi:10.1016/j.it.2006.03.005
7. Ross R. The role of T lymphocytes in inflammation. *Proc Natl Acad Sci U S A*. 1994;91(8):2879. doi:10.1073/pnas.91.8.2879
8. D’Alessio FR, Tsushima K, Aggarwal NR, et al. CD4+CD25+ Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. *J Clin Invest*. 2009;119(10):2898-2913. doi:10.1172/JCI36498
9. Wang Y, Mohan J, Chen C, et al. Neutrophil-to-lymphocyte ratio as a prognostic marker in acute respiratory distress syndrome patients: a retrospective study. *J Thorac Dis*. 2018;10(1):273-282. doi:10.21037/jtd.2017.12.131
10. Billerbeck E, Bottler T, Thimme R. Regulatory T cells in viral hepatitis. *World J Gastroenterol*. 2007;13(36):4858-4864. doi:10.3748/wjg.v13.i36.4858

11. BluestoneJA, Abbas AK. Natural versus adaptive regulatory T cells. *Nat Rev Immunol*. 2003;3(3):253-257. doi:10.1038/nri1032

12. Murai M, Krause P, Cheroutre H, Kronenberg M. Regulatory T-cell stability and plasticity in mucosal and systemic immune systems. *Mucosal Immunol*. 2010;3(5):443-449. doi:10.1038/mi.2010.27

13. Hsieh CS, Liang Y, Tynik AJ, Self SG, Liggitt D, Rudensky AY. Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. *Immunity*. 2004;21(2):267-277. doi:10.1016/j.immuni.2004.07.009

14. Burchill MA, Yang J, Vanberg KB, et al. Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. *Immunity*. 2008;28(1):112-121. doi:10.1016/j.immuni.2007.11.022

15. Lio CW, Hsieh CS. A two-step process for thymic regulatory T cell development. *Immunity*. 2008;28(1):100-111. doi:10.1016/j.immuni.2007.11.021

16. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development and function. *Nature*. 2003;426(6968):577-586. doi:10.1038/nature02213

17. Zheng Y, Josewicz S, Chaudhry A, Peng XP, Forsbush K, Rudensky AY. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. *Nature*. 2010;463:808-812.

18. Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ regulatory T cells that control autoimmune diabetes. *Immunology*. 2000;124(4):431-440. doi:10.1046/s1074-7613(00)80195-8

19. Ngoma AM, Ikeda K, Hashimoto Y, et al. Impaired regulatory T cell reconstitution in patients with acute graft-versus-host disease and cytomegalovirus infection after allogeneic bone marrow transplantation. *Int J Hematol*. 2012;95(1):86-89. doi:10.1007/s11185-011-0976-7

20. Smyth LJ, Eustace A, Kolumb U, Blaikely J, Singh D. Increased airway T regulatory cells in asthmatic subjects. *Chest*. 2010;138(4):905-912. doi:10.1378/chest.09-3079

21. Moradi B, Schnatzer P, Hagmann S, et al. CD4+CD25+/-highCD127low/- regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis joints-analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood. *Arthritis Res Ther*. 2014;16(2):R97. doi:10.1186/ar4545

22. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. *J Exp Med*. 2006;203(7):1693-1700. doi:10.1084/jem.20060468

23. Aerts NE, Dombrecht EJ, Ebo DG, Bridds CH, Stevens WJ, De Clerck LS. Activated T cells complicate the identification of regulatory T cells in rheumatoid arthritis. *Cell Immunol*. 2008;251(2):109-115. doi:10.1016/j.cellimm.2008.04.008

24. Caramalho I, Lopes-Carvalho T, Østler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. *J Exp Med*. 2003;197(4):403-411. doi:10.1084/jem.20021633

25. Amarnath S, Dong L, Li J, Wu Y, Chen W. Endogenous TGF-beta activation by reactive oxygen species is key to Foxp3 induction in TCR-stimulated and HIV-1-infected human CD4+CD25-T cells. *Retrovirology*. 2007;4(1):57. doi:10.1186/1742-4690-4-57

26. Koli K, Myllärniemi M, Keskioja J, Kinnula VL. Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. *Antioxid Redox Signal*. 2008;10(2):333-342. doi:10.1089/ars.2007.1914

27. Li MO, Flavell RA. TGF-beta: a master of all T cell trades. *Cell*. 2008;134(3):392-404. doi:10.1016/j.cell.2008.07.025

28. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. *J Exp Med*. 2005;201(7):1061-1067. doi:10.1084/jem.20042276

29. Chen WJ, Konkel JE. Development of thymic Foxp3(+) regulatory T cells: TGF-beta matters. *Eur J Immunol*. 2015;45(4):958-965. doi:10.1002/eji.201444999

30. Sun CM, Hall JA, Blank RB, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 Treg cells via retinoic acid. *J Exp Med*. 2007;204(8):1775-1785. doi:10.1084/jem.20070602

31. Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, et al. A functionally specialized population of mucosal CD103+DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. *J Exp Med*. 2007;204(8):1757-1764. doi:10.1084/jem.20070590

32. Benson MJ, Pino-Lagos K, Rosenblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced Treg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. *J Exp Med*. 2007;204(8):1765-1774. doi:10.1084/jem.20070719

33. Jeffery LE, Burke F, Mura M, et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and Foxp3. *J Immunol*. 2009;183(9):5458-5467. doi:10.4049/jimmunol.0803217

34. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. *Immunol Rev*. 2010;236(1):219-242. doi:10.1111/j.1600-065X.2010.00923.x

35. Amarnath S, Mangus CW, Wang JC, et al. The PD-1/PD1 axis converts human TH1 cells into regulatory T cells. *Sci Transl Med*. 2011;3(111):111ra120. doi:10.1126/scitranslmed.3003130

36. Yoge V, Frommer F, Lukas D, et al. Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor (+) regulatory T cells. *Immunity*. 2012;37(2):264-275. doi:10.1016/j.immuni.2012.05.025

37. Totsuka T, Kanai T, Makita S, et al. Regulation of murine chronic colitis by CD4+CD25+ regulatory T cells expressing CTLA-4 and Foxp3. *J Immunol*. 2009;183(9):5458-5467. doi:10.4049/jimmunol.0803217

38. Totsuka T, Kanai T, Nemoto Y, et al. Immunosenescent colitogenic CD4(+) T cells convert to regulatory cells and suppress colitis. *Eur J Immunol*. 2005;35(6):1773-1785. doi:10.1002/eji.200425109

39. Totsuka T, Kanai T, Nemoto Y, et al. Immunosenescent colitogenic CD4(+) T cells convert to regulatory cells and suppress colitis. *Eur J Immunol*. 2008;38(5):1275-1286. doi:10.1002/eji.200737914

40. Strober S, Cheng L, Zeng D, et al. Double negative (CD4-CD8-alphabeta+) T cells which promote tolerance
induction and regulate autoimmunity. ImmunoL Rev. 1996;149(1):217-230. doi:10.1111/j.1600-065X.1996.tb00906.x

40. Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, Roncarolo MG. IFN-α and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol. 2001;166(9):5530-5539. doi:10.4049/jimmunol.166.9.5530

41. Fujio K, Okamura T, Yamamoto K. The family of IL-10-secreting CD4+ T cells. Adv Immunol. 2010;105:99-130. doi:10.1016/S0065-2776(10)50004-2

42. Wan YY, Flavell RA. ‘Yin-Yang’ functions of transforming growth factor-β and T regulatory cells in immune regulation. Immunol Rev. 2007;220(1):199-213. doi:10.1111/j.1600-065X.2007.00565.x

43. Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol. 2010;184(7):3433-3441. doi:10.4049/jimmunol.0904028

44. Himmel ME, MacDonald KG, Garcia RV, Steiner TS, Levings MK. Helios+ and Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans. J Immunol. 2013;190(5):2001-2008. doi:10.4049/jimmunol.1201379

45. Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol. 2012;188(3):976-980. doi:10.4049/jimmunol.1202964

46. Yadav M, Louvet C, Davini D, et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med. 2012;209(1713-1722):S1-S19. doi:10.1084/jem.20120822

47. Milpied P, Renand A, Bruneau J, et al. Neuropilin-1 is not a marker of human Foxp3+ Treg. Eur J Immunol. 2009;39(6):1466-1471. doi:10.1002/eji.200839040

48. Yamaguchi T, Hirota K, Nagahama K, et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity. 2007;27(1):145-159. doi:10.1016/j.immuni.2007.04.017

49. Wyss L, Stadinski BD, King CG, et al. Affinity for self-antigen selects Treg cells with distinct functional properties. Nat Immunol. 2016;17(9):1093-1101. doi:10.1038/ni.3522

50. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192(2):303-310. doi:10.1084/jem.192.2.303

51. Sarris M, Andersen KG, Randow F, Mayr L, Betz AG. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity. 2008;28(3):402-413. doi:10.1016/j.immuni.2008.01.012

52. Liang B, Workman C, Lee J, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol. 2008;180(9):5916-5926. doi:10.4049/jimmunol.180.9.5916

53. Bopp T, Becker C, Klein M, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med. 2007;204(6):1303-1310. doi:10.1084/jem.20062129

54. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204(6):1257-1265. doi:10.1084/jem.20062512

55. Sauer AV, Brigida I, Carriglio N, et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood. 2012;119(6):1428-1439. doi:10.1182/blood-2011-07-366781

56. Raker VK, Becker C, Steinbrink K. The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases. Front Immunol. 2016;7:123. doi:10.3389/fimmu.2016.00123

57. Zarek PE, Huang CT, Lutz ER, et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood. 2008;111(1):251-259. doi:10.1182/blood-2007-03-081646

58. Gorelik L, Flavell RA. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000;12(2):171-181. doi:10.1016/S1074-7613(00)80170-3

59. Kuwahara M, Yamashita M, Shinoda K, et al. The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-β and suppresses T(H)2 differentiation. Nat Immunol. 2012;13(8):778-786. doi:10.1038/ni.2362

60. Gregori S, Goudy KS, Roncarolo MG. The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol. 2012;3:30. doi:10.3389/fimmu.2012.00030

61. Meiler F, Zumkehr J, Klunkner S, Rückert B, Akdis CA, Akdis M. In Vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med. 2008;205(12):2887-2898. doi:10.1084/jem.20080193

62. Wirtz S, Billmeier U, Mchelldzide T, Blumberg RS, Neurath MF. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology. 2011;141(5):1875-1886. doi:10.1053/j.gastro.2011.07.040

63. Huang A, Cheng L, He M, Nie J, Wang J, Jiang K. Interleukin-35 on B cell and T cell induction and regulation. J Inflamm (Lond). 2017;14(1):16. doi:10.1186/s12950-017-0164-5

64. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012;13(8):722-728. doi:10.1038/ni.2366

65. Pandilyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+FOXP3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+T cells. Nat Immunol. 2007;8(12):1353-1362. doi:10.1038/ni1536

66. Smeller MC, Lane HC. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother. 2005;28(2):120-128. doi:10.1097/01.jii.0000155049.26787.45

67. Magnani CF, Alberigo G, Bacchetta R, et al. Killing of myeloid APCs via HL-A class I, CD2 and CD226 defines a novel mechanism of suppression by human T regulatory cells. J Immunol. 2011;41(6):1652-1656. doi:10.1002/jem.2041120

68. Adamzik M, Broll J, Steinmann J, et al. An increased alveolar CD4+CD25+FOX3+ T-regulatory cell ratio in acute respiratory distress syndrome is associated with increased 30-day mortality. Intensive Care Med. 2013;39(10):1743-1751. doi:10.1007/s00134-013-3036-3

69. Halter S, Aimade L, Barbé M, et al. T regulatory cells activation and distribution are modified in critically ill patients with...
acute respiratory distress syndrome: a prospective single-Centre observational study. Anaesth Crit Care Pain Med. 2020;39(1):35-44. doi:10.1016/j.accpm.2019.07.014

70. Yu ZX, Ji MS, Yan J, et al. The ratio of Th17/Treg cells as a risk indicator in early acute respiratory distress syndrome. Crit Care. 2015;19(1):82. doi:10.1186/s13054-015-0811-2

71. Wang L, Wang X, Tong L, et al. Recovery from acute lung injury can be regulated via modulation of regulatory T cells and Th17 cells. Scand J Immunol. 2018;88(5):e12715. doi:10.1111/sji.12715

72. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. J Clin Invest. 2002;109(1):41-50. doi:10.1172/JCI0211638

73. Garibaldi BT, D’Alessio FR, Mock JR, et al. Regulatory T cells reduce acute lung injury fibroproliferation by decreasing fibrocyte recruitment. Am J Respir Cell Mol Biol. 2013;48(1):35-43. doi:10.1165/rcmb.2012-0198OC

74. Ehrentraut H, Clambey ET, McNamee EN, et al. CD73+ regulatory T cells contribute to adenosine-mediated resolution of acute lung injury. FASEB J. 2013;27(6):2207-2219. doi:10.1096/fj.12-225201

75. Singer BD, Mock JR, Aggarwal NR, et al. Regulatory T cell DNA methyltransferase inhibition accelerates resolution of lung inflammation. Am J Respir Cell Mol Biol. 2015;52(5):641-652. doi:10.1165/rcmb.2014-0327OC

76. Dial CF, Tune MK, Doerschuk CM, Mock JR. Foxp3+ regulatory T cell expression of keratinocyte growth factor enhances lung epithelial proliferation. Am J Respir Cell Mol Biol. 2017;57(2):162-173. doi:10.1165/rcmb.2017-0019OC

77. Arpaia N, Green JA, Molredo B, et al. A distinct function of regulatory T cells in tissue protection. Cell. 2015;162(5):1078-1089. doi:10.1016/j.cell.2015.08.021

78. Wang L, Zhao L, Lv J, et al. BLT1-dependent alveolar recruitment of CD4(+) CD25(+) Foxp3(+) regulatory T cells is important for resolution of acute lung injury. Am J Respir Crit Care Med. 2012;186(10):989-998. doi:10.1164/rccm.201202-0261OC

79. Hou YC, Pai MH, Liu JJ, Yeh SL. Alanyl-glutamine resolves lipopolysaccharide-induced lung injury in mice by modulating the polarization of regulatory T cells and T helper 17 cells. J Nutr Biochem. 2013;24(9):1555-1563. doi:10.1016/j.jnutbio.2013.01.004

80. Wang L, Shi M, Tong L, et al. Lung-resident mesenchymal stem cells promote repair of LPS-induced acute lung injury via regulating the balance of regulatory T cells and Th17 cells. Inflammation. 2019;42(1):199-210. doi:10.1007/s10753-018-0884-6

How to cite this article: Wang L, Jiang W, Wang X, Tong L, Song Y. Regulatory T cells in inflammation and resolution of acute lung injury. Clin Respir J. 2022;16(9):587-595. doi:10.1111/crj.13527